Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Altimmune Inc.
Altimmune’s hopes of bringing a nasal COVID-19 vaccine to market have been dashed, but it is pivoting to novel peptide-based therapies.
A COVID-19 vaccine in a pill being developed by Vaxart and a nasal spray from Altimmune could offer convenience and maybe even superior immunity compared to injections.
Relay raises $400m to kick off July’s second big week of US initial public offerings. Also, Ocumension and Immunotech launch Hong Kong IPOs, Amgen invests $421m in BeiGene’s $2.08bn offering, Cytokinetics gets up to $400m in deal and investment funding, and Imvax closes $111m series C round.
Currently focused on HBV, Altimmune gets preclinical NASH candidate that offers dual agonism of GLP-1 and glucagon receptors. Nimbus expands alliance with Celgene into IO, Merck & Co. partners with Skyhawk.
- Other Names / Subsidiaries
- Immune Targeting Systems (ITS) Ltd.
- ImmuneFocus Corporation
- PharmAthene Inc.
- Spitfire Pharma, Inc.
- Vaxin Pharmaceuticals
- Vaxin Inc.